Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Minimally invasive suturing for vascular bore closure and heart defect repair

Project description

Safer large-bore vascular closure device

Significant advances in medical technologies have enabled the development of transcatheter procedures to replace open-heart surgeries. These procedures lead to improve clinical results, shorter hospital stays and faster recovery times, however, they require large access sites in the vessels. Closure of these large access sites is associated with a high rate of complications. The EIC-funded NVCD project will develop a proprietary micro-suturing technology to achieve more efficient and safer large-bore vascular closure. Following prototype development and preclinical validation, the project will conduct clinical trials to obtain CE certification for commercial deployment of the suturing device.

Objective

Cardiovascular diseases (CVDs) remain a major health problem worldwide and a leading cause of mortality, with over annual 18 million deaths. In Europe, CVDs are associated with 4 million deaths and costs of around 210 billion per year.
Many surgeries to treat cardiac conditions are shifting to be minimally invasive and this is a trend expected to continue growing due to its multiple advantages over open interventions. However, as newly developed devices for transcatheter procedures become bigger they also require larger vascular access sites. A couple of devices are used in vascular large-bore closure (e.g. ProGlide from Abbott). However, they are associated with still high vascular and bleeding complications (up to 20%, depending on the operators skills). Such complications are linked to longer hospitalizations, unnecessary suffering, and greater healthcare costs (20k per patient), as well as higher morbidity and mortality.
To solve this persistent unmet need in the field of cardiovascular surgery, Novelrad has specifically developed the NVCD closure device. It integrates a proprietary and revolutionary micro-suturing technology that mimics the standard surgical technique, effectively delivering a multipoint continuous suture in a minimally invasive manner. The NVCD is easy to use and enables a safer closure of large bores, potentially reducing complication rates to 3%, saving up to 15 min in the procedure, and bringing important cost savings related to same-day discharge and complications management. Importantly, with a single NVCD device large and extra-large bore closure of veins and arteries is possible (up to 30Fr).
After obtaining a fully functional prototype of the NVCD and advancing in pre-clinical tests, we now aim to perform a first-in-human (FIH) study and complete the clinical trial required to obtain its CE certification as a Class III medical device. This will be crucial to prepare for industrialization and commercial deployment in Europe and globally.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

NOVELRAD LTD
Net EU contribution
€ 2 499 999,00
Address
KIBBUTZ METZER
3882000 METZER
Israel
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 4 121 068,75